The company has other products already, and even other new products in the pipeline, so the company has a certain value even if the latest expectation all are waiting for at the moment shouldn't pass the FDA approval etc... I mean thought logically... The decision (presentation of the data for this new drug product against Alzheimer disease) will fall mid November as stated in the FDA calendar (cf. link in posting #3 by CET above and search therein for CRTX).
A maybe subjective percentual value for the company after the D-Day decision. If it is now 100% (at spot 75) and the FDA decision is negative then company will IMO still be at least 30% worth (ie. spot then about 22.50)
Yep, unfortunately atm I'm practically grounded, lack of enough funds for options... :-( If anybody wants to hire me as options guy (picker/researcher/analyzer/coder/programmer/developer) you are welcome... Need to make some bucks ASAP to get back into the game... Currently doing stocks only with a mini acct, boring... :-(
gut-brain axis is a hot topic in neuroscience - i'm willing to gamble some fun-money that CRTX delivers a home-run with Atuzaginstat. let's go! long CRTX
Read in a German news article below that such a drug for Alzheimer's disease has a huge market potential of about 10 billion USD, ie. there's much/urgent need for such a product. https://www.faz.net/aktuell/wirtsch...-von-us-behoerde-fda-zugelassen-17377935.html